Early onset of efficacy during titration in US phase 3 open-label InfusON trial of apomorphine subcutaneous infusion for Parkinson’s disease motor fluctuations
Objective: Evaluate safety/onset of efficacy during titration of continuous subcutaneous apomorphine infusion (CSAI) for motor fluctuations in U.S. outpatients with Parkinson’s disease (PD). Background: Global…Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease, in a movement disorder unit in Spain
Objective: To determine the number of patients that maintain infusion therapies (continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel (LCIG)) as treatment for advanced…The effect of continuous subcutaneous apomorphine infusion on vitamin B metabolites and plasma homocysteine in Parkinson’s disease patients
Objective: To evaluate the plasma level of vitamin B and homocysteine between PD patients with conventional medications and PD patients with CSAI. Background: Although levodopa…Clinic versus home dose optimization of apomorphine sublingual film in Parkinson’s Disease: cross-study comparison of safety
Objective: To compare the safety profile of clinic versus home dose optimization of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease experiencing OFF episodes.…Apomorphine sublingual film for OFF episodes in PD: Impact on orthostatic hypotension during dose-optimization
Objective: To assess the occurrence of orthostatic hypotension (OH) during apomorphine sublingual film (SL-APO) dose-optimization in patients with Parkinson’s disease (PwPD). Background: SL-APO has been…Apomorphine effects on Parkinson’s disease fluctuation related pain: a pilot study
Objective: To evaluate the effect and safety of subcutaneous apomorphine as a treatment for fluctuation-related pain in Parkinson's disease (PD). Background: Pain is one of…May apomorphine be helpful for the axial symptoms of Parkinson’s Disease?
Objective: To assess the effect of continuous subcutaneous infusion of apomorphine on axial symptoms of Parkinson Disease. Background: Axial symptoms of Parkinson’s Disease may be…Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series
Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…Apomorphine Hydrochloride Injection Treatment Initiations in the Presence and Absence of an Antiemetic in People with Parkinson Disease
Objective: To provide real-world experience regarding apomorphine treatment initiations with or without concomitant antiemetic prophylaxis. Background: Apomorphine hydrochloride (apo) injection, administered subcutaneously, is an “on-demand’…Adverse drug reactions to apomorphine: a worldwide pharmacovigilancedatabase analysis
Objective: To determine the safety profile of apomorphine (expected vs. new signals), regardless of the indication and route of administration. Background: Adverse drug reactions (ADR)…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 13
- Next Page »